BUY Alembic Pharmaceuticals Limited — Kshitija Salvi, Globe Capital Market
byKshitija Salvi, Globe Capital MarketHorizon: NA (inferred Swing (≤2wk))4 Aug 2026via CNBC Awaaz.
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
Alembic Pharmaceuticals reported a 26% YoY increase in revenue to Rs. 2150 Cr and a 12% YoY increase in Profit After Tax to Rs. 173 Cr for Q1 FY27. EBITDA also saw a 21% YoY rise. The company highligh
BSE · Company Update·4 Aug · 2d ago
Alembic Pharmaceuticals reported Q1 FY27 financial results with revenue up 26% to Rs. 2150 Cr and EBITDA up 21% YoY. The company highlighted strong growth across businesses, driven by volume growth an
BSE · Company Update·4 Aug · 2d ago
Alembic Pharma gains on USFDA nod for generic constipation drug targeting $100 million US market
NewsCnbc-Tv18·28 Jul · 1w ago
Alembic Pharmaceuticals Ltd has received final approval from the USFDA for its Prucalopride Tablets in 1 mg and 2 mg strengths.
BSE · Company Update·28 Jul · 1w ago
Alembic Pharmaceuticals Limited announced the approval of its consolidated and standalone unaudited financial results for the quarter ended June 30, 2026, along with the Limited Review Report from sta
NSE · Outcome of Board Meeting·4 Aug · 2d ago
Alembic Pharmaceuticals Ltd announced the approval of its consolidated and standalone unaudited financial results for the quarter ended June 30, 2026, along with the Limited Review Report from statuto
BSE · Board Meeting·4 Aug · 2d ago
Alembic Pharmaceuticals Limited's Board of Directors has approved the Consolidated and Standalone Unaudited Financial Results for the quarter ended June 30, 2026, along with the Limited Review Report
NSE · Outcome of Board Meeting·4 Aug · 2d ago
Nothing found in this tip’s window yet.
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.